Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's TrapTx™ Analyzer System uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.